OM336 in Seropositive Autoimmune Diseases
Recruiting
Phase 1
Interventional Study
Sjogrens Disease
Idiopathic Inflammatory Myopathy (IIM)
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
At a Glance
- Age
- 18 – 75
- Sex
- Any
- Trial phase
- Phase 1
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 39 (estimated)
- Sponsor
- Lakefront Biotherapeutics West LLC · Industry
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
An early-phase clinical trial evaluating the safety, tolerability, and pharmacokinetics of OM336 in adult participants with seropositive autoimmune diseases. OM336 is administered subcutaneously in ascending dose cohorts.
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Key Inclusion Criteria:
* Diagnosis of active seropositive autoimmune disease
* Relapsed/refractory after ≥2 prior/ongoing treatments
* Body weight ≥ 50 kg
* Willing to comply with and study requirements and procedures
Key Exclusion Criteria:
* Previous treatment with a BCMA-targeted therapy
* Cl…
Contacts